+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors



Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors



Clinical Rheumatology 37(6): 1617-1623



The aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) for patients with inflammatory rheumatic disease newly initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARD). This was a retrospective cohort study that extracted data for new users of TNFi between 1 August 2010 and 31 August 2016 from the Australian Optimising Patient outcome in Australian RheumatoLogy (OPAL) registry. Patients were 1:1 propensity-score matched with golimumab based on their age, sex, year of index, C-reactive protein level, baseline treatment combination and disease. Treatment persistence was calculated. Data from 3749 patients were extracted (adalimumab n = 1518; certolizumab n = 298; etanercept n = 1068; golimumab n = 865). The mean (SD) ages of patients were 51.7 (14.2) years for adalimumab, 53.7 (14.0) years for certolizumab, 52.8 (14.3) years for etanercept and 52.3 (14.6) years for golimumab, with disease durations 7.7 (10.5), 8.8 (9.2), 8.1 (10.4) and 7.3 (9.7) years, respectively. Two thirds of the patients were women. There was no significant difference in treatment persistence by treatment in the overall population (adalimumab 33.6 [95% CI 28.6-40.7], certolizumab 24.8 [95% CI 21.3-42.1], etanercept 27.6 [95% CI 23.4-36.5], golimumab 30.3 [95% CI 23.26-36.5]; months, p = 0.545), or in the propensity score-matched population. No safety signals were detected. In this real-world biologic-naïve Australian inflammatory rheumatic disease cohort treated with subcutaneous TNF inhibitors during the period 2010-2016, there was no difference in treatment persistence between agents.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065639476

Download citation: RISBibTeXText

PMID: 29667098

DOI: 10.1007/s10067-018-4105-3


Related references

Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatology 1: 163-178, 2009

FRI0353Association of Attitudes Toward Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and Tumor Necrosis Factor Inhibitors and Treatment Adherence in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: Results from the Global Align Study:. Annals of the Rheumatic Diseases 74(Suppl 2): 553.2-554, 2015

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Plos one 12(2): E0169830, 2017

AB1163Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab. Annals of the Rheumatic Diseases 74(Suppl 2): 1291.3-1292, 2015

AB0272Anti-Rheumatic Treatment Is Not Associated with Reduction of Pentraxin 3 (PTX3) in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA) and Ankylosing Spondylitis (AS). Annals of the Rheumatic Diseases 75(Suppl 2): 992.3-993, 2016

The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clinical Rheumatology 38(2): 297-305, 2019

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Rheumatology 43(12): 2120-2130, 2016

OP0169Association between Use of Disease-Modifying Anti-Rheumatic Drugs and Diabetes in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, or Psoriasis/psoriatic Arthritis: Nationwide, Population-Based Cohort Study of 84,989 Patients: Table 1. Annals of the Rheumatic Diseases 75(Suppl 2): 119.3-120, 2016

SAT0130Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohns disease:. Annals of the Rheumatic Diseases 71(Suppl 3): 514.3-515, 2013

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases 72(4): 517-524, 2013

Golimumab Utilization Patterns And Refill Adherence In Patients With Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis. Value in Health 17(3): A49-A50, 2014

AB1067Golimumab Utilization Patterns and Refill Adherence in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. Annals of the Rheumatic Diseases 73(Suppl 2): 1154.1-1154, 2014

The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Practice and Research. Clinical Rheumatology 30(5): 802-825, 2016

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Journal of Rheumatology 33(11): 2167-2172, 2006

Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Expert Opinion on Drug Safety 10(4): 655-673, 2011